Fig. 2: Pre-existing clone with biallelic TNFRSF17 deletion drives MM relapse after anti-BCMA TCE therapy in patient MM-2.
From: Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
a, ScCNV-seq heatmap comparing the CN changes in chromosomes 1–22 in pre-therapy (pre) versus post-relapse (post) CD138+ MM cells. b, Pre-therapy and post-relapse CD138+ CN alteration at TNFRSF17 locus based on scCNV-seq. The barplot and table compare the percentages of cells harboring the CNVs in pre- versus post-CAR T/ TCE relapse samples. c, Fish plot of clonal phylogeny of the CD138+ cells at pre-therapy versus post-relapse timepoints inferred from scCNV-seq data. The associated tree illustrates the main alterations differentiating each clone. d, Pre- versus post-relapse CD138+ BCMA protein expression (by monoclonal anti-BCMA antibody, clone 19F2) using flow cytometry. ctrl, control.
